Miglustat reversibly inhibits glucosylceramide synthase, the enzyme that catalyses the first committed step in GSL biosynthesis, and was previously shown to slow disease progression in Sandhoff disease mice [8,9,10]. Here, UGCG is linked to Sandhoff disease.